INTRODUCTION
Deregulated apoptosis and uncontrolled growth play a pivotal role in the development of aggressive NB tumors. This enhanced growth is in part induced by aberrant expression of neurotrophic factors. Among these, brain-derived neurotrophic factor (BDNF) and its cognate receptor NTRK2/TrkB have been shown to correlate with poor prognosis and resistance to chemotherapeutic agents (Li et al., 2005; Schramm et al., 2005) . BDNF/TrkB induces survival signaling via the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB) pathway. Recently, a retrospective study suggests that phosphorylation of PKB at serine 473 and/or threonine 308 may be a prognostic indicator of decreased event-free or overall survival in NB (Opel et al., 2007) . Substrates of AKT1/PKB, in particular the members of the FoxO transcription factor family, FOXO1/FKHR, FOXO3/FKHRL1, and FOXO4/ AFX, are downstream components of neurotrophin receptor signaling (Zheng et al., 2002; Gilley et al., 2003) . We and others have shown that FKHRL1 is phosphorylated by hyperactive PKB in malignant NB (Li et al., 2005; Obexer et al., 2007) . The phosphorylation by PKB causes association of FKHRL1 with 14-3-3 proteins, export from the nucleus and repression of FKHRL1 target gene transcription (van der Horst and Burgering, 2007) . In the absence of active PKB, FKHRL1 regulates the expression of proteins that are involved in cell cycle arrest, cell division, protection against oxidative stress, and apoptosis (van der Horst and Burgering, 2007; Huang and Tindall, 2007) .
Apoptosis is a cellular process regulated either via membrane death receptors or by the balance of pro-and antiapoptotic proteins of the BCL2 family. This protein family is divided into two subgroups: one subgroup is the so-called "multidomain" family that consists of proapoptotic members such as BAX and BAK1/Bak and prosurvival proteins, e.g., BCL2, BCL2L1/Bcl-xl, and MCL1. The other subgroup is the BH3-only family, a large group of apoptosis-inducers such as PMAIP1/Noxa and BCL2L11/Bim that are activated by various stimuli. On cell death decision, cytochrome c is released from mitochondria and induces the formation of the so-called "apoptosome" complex leading to caspase-9 cleavage and activation of effector caspases. The activity of caspases is counteracted by members of the inhibitor of apoptosis protein (IAP) family. In contrast to other IAPs, BIRC5/Survivin contains only a single baculovirus IAP repeat (BIR) and lacks the RING domain. Its apoptosis-protecting function therefore is still under debate: Survivin was shown to inhibit effector caspases via its single BIR domain, but it also was shown to act upstream at the level of mitochondria (Shankar et al., 2001; Liu et al., 2004) . Survivin is frequently expressed in various malignancies, among them NB (Adida et al., 1998; Islam et al., 2000) . The Survivin gene is located at 17q25 and in NB, gain of chromosome 17q or the distal translocation of 17q is of prognostic relevance and correlates with aggressive tumors (Islam et al., 2000) .
Because activated PKB protects NB cells from chemotherapy-induced apoptosis and both active PKB and Survivin are predictive for an adverse clinical outcome, we analyzed a possible connection between PKB and Survivin.
MATERIALS AND METHODS

Cell Lines, Culture Conditions, and Reagents
The NB cell lines SH-EP (kindly provided by Dr. N. Gross, Pediatric Oncology Research, Pediatric Department, University Hospital CHUV, Lausanne, Switzerland) and STA-NB15 (kindly provided by Dr. P. Ambros, St. Anna Children's Hospital, Vienna, Austria) (Narath et al., 2005) as well as Phoenix packaging cells for helper-free production of amphotropic retroviruses (Grignani et al., 1998) were cultured in RPMI 1640 medium (Lonza Verviers SPRL, Verviers, Belgium) containing 10% fetal calf serum (Invitrogen, Paisley, United Kingdom), 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM l-glutamine at 5% CO 2 . All cultures were routinely tested for mycoplasma contamination with the Venor R GeM-mycoplasma detection kit (Minerva Biolabs, Berlin, Germany).
Expression Constructs
The vectors pLIB-FKHRL1(A3)-ERtm-iresNeo and pQ-tetH1-SV40Puro have been described previously (Obexer et al., 2007) . The pLIB-MCS2-iresYFP plasmid was constructed by inserting an iresYFP cassette into the BamHIXhoI sites of the pLIB-MCS2 plasmid. Survivin cDNA was amplified from a liver cDNA library (Clontech, Mountain View, CA) by using the primers 5Ј-TATAGAATTCATGGGTGCCCCGACGTTG-3Ј (forward) and 5Ј-TAT-AGTCGACTCAATCCATGGCAGCCAGC-3Ј (reverse) and cloned into the EcoRI-SalI sites of the pLIB-MCS2-iresYFP plasmid. For construction of the pQ-tetH1-shSurvivin-SV40Puro vector, oligonucleotides coding for short hairpin RNA (shRNA) double strands containing the Survivin-specific sequence GCATTCGTCCGGTTGCGCT were annealed and inserted into the MunI-BamHI sites of the pQ-tetH1-SV40Puro vector. To obtain the pGL3-survivin-promoter-Luc, a 1900 bp fragment (Ϫ1828 to ϩ81) of the human survivin promoter was amplified and inserted into the BglII-HindIII sites of the pGL3-basic plasmid. pLIB-ECFP-FKHRL1-iresPuro was constructed by inserting the FKHRL1 wild-type cDNA from the pECE-HA-FKHRL1 vector (Dijkers et al., 2002) into the MunI-SalI sites of the pLIB-ECFP-MCS2-iresPuro.
Following a recommendation by the HUGO Gene Nomenclature Committee, all official human gene symbols are put in uppercase letters to distinguish them from their often more widely used aliases, e.g. BIRC5 ϭ Survivin.
Production of Retroviruses and Retroviral Infection
Phoenix cells (6.5 ϫ 10 5 ) were transfected with 2 g of pLIB-Survivin-iresYFP, pLIB-MCS2-iresYFP, pQ-tetH1-shSurvivin-SV40Puro, pQ-tetH1-SV40Puro, pLIB-FKHRL1(A3)-ERtm-iresNeo, pLIB-ECFP-FKHRL1-iresPuro, or pLIB-MCS2-iresNeo by using Lipofectamine2000 (Invitrogen). After 48 h, the retrovirus-containing supernatants were filtered through 0.22 m syringe filters (Sartorius, Gö ttingen, Germany). pLIB-Survivin-iresYFP and control pLIB-MCS2-iresYFP supernatants were used to infect SH-EP/FKHRL1 (SH-EP/ FKHRL1-Surv and SH-EP/FKHRL1-Ctr) and SH-EP (SH-EP-Surv, SH-EPCtr) cells. To knock down Survivin, SH-EP/FKHRL1 cells were infected with the retrovirus vector pQ-tetH1-shSurvivin-SV40Puro or the control plasmid pQ-tetH1-SV40Puro (SH-EP/FKHRL1-shSurv, SH-EP/FKHRL1-shCtr). To generate SH-EP/ECFP-FKHRL1 cells for live cell fluorescence analysis of FKHRL1 subcellular localization, SH-EP cells were infected with pLIB-ECFP-FKHRL1-iresPuro retroviral supernatants. Cells infected with the pLIB-Survivin-iresYFP vector (SH-EP and SH-EP/FKHRL1) were enriched to Ͼ95% by fluorescence-activated cell sorting (FACS) using an FACS Vantage cell sorter (BD Biosciences, San Jose, CA).
Determination of Apoptosis
Apoptosis was determined by propidium iodide (PI) staining of nuclei and forward/sideward scatter analysis by using a Cytomics FC-500 Series Flow Cytometry System (Beckman Coulter, Fullerton, CA). The experiments were performed as described previously (Ausserlechner et al., 2004) . Mitochondrial activity was assessed by the fluorescence dye MitoTracker Red/CMX-Ros (Invitrogen) according to the manufacturer's instructions.
Luciferase Reporter Assay
SH-EP/Ctr and SH-EP/FKHRL1 cells (6 ϫ 10 5 ) were transfected with 3 g of pGL3-survivin-promoter-Luc DNA by using Lipofectamine2000 (Invitrogen). Sixteen hours after transfection, the cells were washed and incubated in presence or absence of 75 nM 4-hydroxy tamoxifen (4OHT) for 24 h. Luciferase activity was assessed using the Luciferase Assay System (Promega, Madison, WI).
Live Cell Fluorescence Microscopy
Imaging of living cells was done using an Axiovert200M microscope (Carl Zeiss, Jena, Germany) equipped with a CO 2 chamber and Axiovision 4.6 software (Carl Zeiss). The cells were seeded on glass slides coated with 0.1 mg/ml collagen 1 d before performing the experiments.
Subcellular Fractionation and Immunoblotting
Cytoplasmic and mitochondrial fractions were prepared as follows: 5 ϫ 10 7 cells were incubated in MSH buffer (210 mM mannitol, 70 mM sucrose, 20 mM HEPES, and 1 mM EDTA, pH 7.4) with protease and phosphatase inhibitors on ice for 1 h. Nuclei and nonlysed cells were removed by centrifugation at 500 ϫ g for 5 min. To obtain the mitochondrial fraction, the supernatant was centrifuged at 25,000 ϫ g for 30 min. The membrane pellet was resuspended in MSH buffer containing protease inhibitor and 1% CHAPS, lysed on ice for 30 min, and centrifuged at 25,000 ϫ g for 30 min. Protein concentration was measured using Bradford reagent.
Cytoplasmic and nuclear extracts were prepared using the ProteoJet cytoplasmic and nuclear protein extraction kit (MBI Fermentas, St. Leon-Rot, Germany). Cell extracts for immunoblot analysis were prepared as described previously (Ausserlechner et al., 2004) . Samples were separated by SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes by a Hoefer semidry blotting apparatus. The membranes were incubated with primary antibodies specific for Survivin (R&D Systems, Minneapolis, MN), BAX (Cell Signaling Technology, Danvers, MA), Bim (BD Biosciences Pharmingen, San Diego, CA), cytochrome c, Cox4 (Clontech), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Novus Biologicals, Littleton, CO), and ␣-tubulin (Oncogene Science, Cambridge, MA); washed; and incubated with anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Chalfont St. Giles, Buckinghamshire, United Kingdom). The blots were developed using enhanced chemiluminescence (GE Healthcare) and analyzed in an AutoChemi system (UVP, Cambridge, United Kingdom). Densitometry of 16-bit digital images was performed using LabWorks 4.6 software (UVP).
Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis
SH-EP/FKHRL1 and NB15/FKHRL1 cells were cultured in the presence of 75 nM 4OHT for 0, 3, 6, and 8 h, respectively. Total RNA was isolated from 5 ϫ 10 6 cells by using TRIzol reagent (Invitrogen), and cDNA was synthesized from 1 g of total RNA by using the RevertAid kit (MBI Fermentas). RT-PCR was performed on the iCycler instrument (Bio-Rad, Munich, Germany) by using the Survivin (forward 5Ј-CCACTGAGAACGAGCCAGACTTG-3Ј and reverse 5Ј-AGAAAGGAAAGCGCAACCGG-3Ј), and GAPDH oligonucleotides (forward 5Ј-TGTTCGTCATGGGTGTGAACC-3Ј and reverse 5Ј-GCA-GTGATGGCATGGACTGTG-3Ј).
RESULTS
Inhibition of the PI3K-PKB Axis Activates FKHRL1 and Represses Survivin in Human NB Cells
We demonstrated before that in the NB cell lines SH-EP and STA-NB15 FKHRL1 is hyperphosphorylated at S253 and T32, suggesting its inactivation by PKB (Obexer et al., 2007) . To investigate, whether this phosphorylation status coincides with cytoplasmic localization of FKHRL1, we constructed an ECFP-FKHRL1 fusion protein and studied FKHRL1 subcellular distribution as a marker of activation in living cells. In untreated SH-EP/ECFP-FKHRL1 cells FKHRL1 localized almost exclusively to the cytoplasm (Figure 1A ). On treatment with the PI3K-inhibitor Ly294002, ECFP-FKHRL1 almost completely translocated to the nucleus within 40 min, suggesting rapid activation of this transcription factor upon loss of PI3K survival signaling. In concordance with the ECFP-FKHRL1 fusion protein, also endogenous FKHRL1 accumulated in the nuclear fraction of Ly294002-treated SH-EP cells (Figure 1B) . At a concentration of 40 M Ly294002 the phosphorylation of PKB at serine 473 was completely lost, suggesting that at this concentration PKB is mainly present in its inactive form ( Figure 1B, right) .
Because Survivin was reported to be a downstream target of PI3K-PKB signaling, we analyzed whether blockage of PI3K activity affects Survivin steady-state protein expression in NB cells. As shown in Figure 1C , Ly294002 treatment markedly repressed Survivin steady-state levels within 2 h, both in SH-EP and STA-NB15 cells. Because FKHRL1 activation preceded Survivin repression, we next studied whether FKHRL1 may regulate Survivin expression in NB cells.
Conditional FKHRL1(A3)ERtm Induces Apoptotic Cell Death and Decreases Survivin mRNA and Protein in SH-EP and STA-NB15 Cells
To study, whether FKHRL1 contributes to Survivin repression, we infected SH-EP and STA-NB15 cells with a retrovirus coding for a 4OHT-regulated, phosphorylation-independent FKHRL1(A3)ERtm allele (Obexer et al., 2007) . Activation of transgenic FKHRL1(A3)ERtm by 75 nM 4OHT induces its accumulation in the nucleus within 2 h ( Figure  2A ) and programmed cell death in SH-EP/FKHRL1 and NB15/FKHRL1 cells within 48 -72 h ( Figure 2B ). Similar to endogenous FKHRL1 in Ly294002-treated cells (Figure 1B, left) , only a fraction of 4OHT-treated FKHRL1(A3)ERtm accumulated in the nucleus, suggesting that partial activation of FKHRL1 suffices to exert a pronounced physiological effect.
As shown in Figure 3A , activation of transgenic FKHRL1(A3)ERtm reduced endogenous Survivin expression within 8 h and strongly repressed it after 24 and 36 h (38 and 9% of controls, respectively), which correlated with an increase of apoptosis at these time points in SH-EP/FKHRL1 cells. In NB15/FKHRL1 cells, Survivin decreased after 36 h of 4OHT-treatment to 34% of controls, which correlated with the later onset of nuclear fragmentation in these cells.
Next, we addressed by quantitative RT-PCR, whether the reduction of Survivin protein was due to transcriptional repression: Survivin mRNA was repressed within 6 h in SH-EP/FKHRL1 and within 3 h in NB15/FKHRL1 cells ( Figure 3B ). To assess whether Survivin repression was due to reduced survivin promoter activity, a luciferase reporter plasmid harboring 1900 bp of the human survivin promoter was transfected into SH-EP/FKHRL1 and SH-EP/Ctr cells. On FKHRL1 activation, basal survivin promoter activity was reduced to 12% of untreated controls ( Figure 3C ). Because the repression of Survivin by FKHRL1 can be blocked by cycloheximide treatment ( Figure 3D ), a newly synthesized cofactor might be essential for FKHRL1-mediated transcriptional repression, suggesting that FKHRL1 indirectly reduces Survivin promoter activity.
Transgenic Expression of Survivin Inhibits FKHRL1-induced Apoptosis
Survivin was introduced into SH-EP/FKHRL1 cells by using a retroviral bicistronic vector that expresses Survivin and the yellow fluorescent protein (YFP). In these cells, the repression of Survivin during FKHRL1 activation was efficiently prevented for 36 h ( Figure 4A ). Ectopic Survivin protected SH-EP/FKHRL1 cells against FKHRL1-induced apoptosis, reducing the number of apoptotic cells from 50 to Ͻ10% after 48 h and to 15% after 72 h of 4OHT treatment ( Figure  4B ). In contrast to its antiapoptotic effect in SH-EP/FKHRL1 cells, transgenic Survivin did not significantly affect the antiproliferative effect of FKHRL1 as measured by [ 3 H]thymidine incorporation (see Supplemental Figure) , suggesting that loss of Survivin does not contribute to FKHRL1-induced cell cycle arrest. The strong induction of the cell cycle inhibitor p27
Kip1 ( Figure 5D ) might also explain why overexpression of Survivin has no significant impact on the antiproliferative effect of FKHRL1. To further investigate dosedependent effects of Survivin, we lowered endogenous Survivin expression by retroviral shRNA technology.
Knockdown of Endogenous Survivin Sensitizes SH-EP Cells to FKHRL1-induced Apoptosis
To study whether Survivin steady-state levels determine sensitivity of NB cells to FKHRL1-induced apoptosis, we infected SH-EP/FKHRL1 cells either with a SurvivinshRNA-expressing or an empty pQ-tetH1-SV40Puro retrovirus. Bulk-selected SH-EP/FKHRL1-shSurv cells showed markedly reduced endogenous Survivin expression compared with mock-infected controls ( Figure 5A ). We next assessed whether lowering the 4OHT dose to activate transgenic FKHRL1(A3)ERtm affects cell death kinetics. 4OHT (75 nM) induced 49% apoptosis after 48 h ( Figure 2B ). As shown in Figure 5B , addition of only 20 nM 4OHT reduced programmed cell death to 11% after 48 h. This indicates that the ability of FKHRL1 to induce apoptosis is dose dependent. Importantly, in Survivin-shRNA-expressing SH-EP/FKHRL1-shSurv cells 20 nM 4OHT markedly increased apoptosis compared with controls with 54% apoptotic cells after 48 h. This is comparable with the death rate induced by a threefold higher 4OHT concentration ( Figure 2B ). The knockdown of Survivin not only increased nuclear fragmentation as a hallmark of apoptosis but also accelerated the loss of mitochondrial membrane potential during FKHRL1-activation as shown in Figure 5C . To assess, whether reduced cell death at 20 nM 4OHT corresponds with reduced activity of ectopic FKHRL1(A3)ERtm, we assessed steady-state protein levels of Survivin and p27
Kip1 in cells treated with 20 or 75 nM 4OHT, respectively ( Figure 5D ). After 8 h in presence of 75 nM 4OHT, Survivin was decreased to 52% of control, whereas with 20 nM 4OHT Survivin steady-state levels remained unchanged. However, after 24 h, Survivin expression was lowered to 35 and to 15% of untreated controls with 20 and 75 nM 4OHT, respectively. p27 Kip1 was strongly induced at both concentrations after 24 h. However, with 75 nM 4OHT approximately twofold higher protein levels were achieved compared with 20 nM 4OHT, suggesting a dosedependent gene regulation by FKHRL1(A3)ERtm. The combined data demonstrate that cellular Survivin steady-state levels are rate limiting for FKHRL1-induced apoptosis in NB cells.
Survivin Purifies with the Mitochondrial Compartment and Affects Mitochondrial Accumulation of Proapoptotic BCL2 Proteins
In SH-EP/FKHRL1 cells, FKHRL1-induced apoptosis is associated with loss of mitochondrial membrane potential, cytochrome c release, and cleavage of caspase-9 (Obexer et al., 2007) . We therefore studied whether transgenic Survivin may prevent apoptosis upstream of caspases by preserving mitochondrial activity during FKHRL1-induced apoptosis. On FKHRL1 activation, the number of CMX-Ros-negative cells was markedly reduced in the population of Survivinoverexpressing cells after 48 h (42.2%) compared with controls (13.4%), suggesting that transgenic Survivin expression affects apoptosis signaling at the level of mitochondria (Figure 6A ). In concordance with the CMX-Ros staining, Survivin prevented the appearance of cytoplasmic cytochrome c after 8 and 24 h ( Figure 6B ). We described before that the BH3-only protein Bim is strongly induced 8 h after FKHRL1 activation in SH-EP and STA-NB15 cells (Obexer et al., 2007) . Interestingly, in SH-EP/FKHRL1-Surv cells Bim was present in the mitochondrial fraction at lower levels than in SH-EP/ FKHRL1-Ctr cells. BAX was found equally distributed between cytoplasm and mitochondria in SH-EP/FKHRL1-Surv cells, and no accumulation at the mitochondria upon FKHRL1 activation was observed at the investigated time points (Figure 6B , top). As described for other cell types (Dohi et al., 2007) , Survivin purified with cytoplasmic and mitochondrial preparations ( Figure 6B, bottom) . After 24 h of 4OHT-treatment in SH-EP/FKHRL1-Ctr cells Survivin was reduced both in the cytoplasmic and the mitochondrial fraction, whereas in SH-EP/FKHRL1-Surv cells Survivin repression was only visible in the cytoplasmic fraction. The combined data demonstrate that a pool of Survivin localizes to the mitochondria, affects the expression of the proapoptotic BCL2 proteins Bim and Bax, and delays the release of cytochrome c into the cytoplasm in NB cells.
Survivin Repression Is Critical for FKHRL1-enhanced Sensitivity to Doxorubicin and Etoposide
Because hyperactivation of the PI3K-PKB pathway has been shown to protect NB cells from chemotherapy-induced cell death (Li et al., 2007) , we studied whether FKHRL1 may influence the sensitivity to chemotherapy. SH-EP cells were treated with the drugs doxorubicin, etoposide, and vinblastine and transgenic FKHRL1(A3)ERtm was activated by 50 nM 4OHT. FKHRL1 per se induced ϳ15% apoptosis within 24 h compared with 2% in the untreated controls ( Figure  7A ). Treatment with 2.5 g/ml etoposide or 0.25 g/ml doxorubicin induced 8 and 12% apoptosis, respectively, whereas 50 ng/ml vinblastine treatment increased cell death to ϳ31% within 24 h. However, when FKHRL1 was activated by 4OHT, sensitization to doxorubicin-and etoposidetreated cells was observed, raising apoptosis levels to Ͼ50% within 24 h. In contrast, active FKHRL1 did not markedly elevate vinblastine-induced apoptosis. This suggests that FKHRL1 sensitizes neuroblastoma cells specifically to DNAdamaging agents such as doxorubicin and etoposide. We next asked whether Survivin may protect NB cells against doxorubicin-and etoposide-induced apoptosis. For that purpose, we stably overexpressed Survivin in SH-EP cells (Figure 7B ) and subjected these cells to doxorubicin, etoposide, and vinblastine treatment for 48 h. As shown in Figure 7C , Survivin exerted a protective effect on doxorubicin-and etoposide-treated cells but only slightly lowered vinblastineinduced cell death after 48 h, suggesting a critical role of Survivin in the death pathways activated by these drugs. The fact that FKHRL1 strongly represses Survivin and sensitizes NB cells to doxorubicin-and etoposide-induced apoptosis together with the observation that Survivin overexpression specifically inhibits cell death by these DNAdamaging drugs suggests a role of Survivin in FKHRL1-mediated drug sensitization. To address this question in detail, SH-EP/FKHRL1-Ctr and SH-EP/FKHRL1-Surv cells were cultured for 48 and 72 h in presence or absence of 50 nM 4OHT and/or doxorubicin and/or etoposide (Figure 7 , D and E). In controls, the activation of FKHRL1 induced 52% apoptosis within 48 h, which was further increased to 73 and 69% by the combination with doxorubicin or etoposide, respectively. Transgenic Survivin markedly reduced FKHRL1-induced apoptosis after 48 h from 52 to 9% and reduced apoptosis rates from 73 to 34% in doxorubicin/4OHT and from 69 to 26% in etoposide/4OHT-treated cells. This protection by transgenic Survivin was apparent up to 72 h of 4OHT treatment ( Figure 7E ). The combined data suggest that Survivin repression by FKHRL1 contributes to enhanced drug sensitivity of NB cells.
DISCUSSION
PKB hyperactivation contributes to chemotherapy resistance of malignant NB and has been implied as a prognostic marker for decreased event-free survival (Opel et al., 2007) . We have shown recently that the PKB downstream target FKHRL1 induces apoptosis by up-regulating the BH3-only proteins Bim and Noxa in NB cells (Obexer et al., 2007) . FKHRL1 is retained in the cytoplasm in NB cells but rapidly translocates into the nucleus upon inhibition of PI3K ( Figure  1, A and B) and represses the antiapoptotic protein Survivin (Figure 3) . In primary NB cells, Survivin expression correlates with adverse clinical factors, advanced disease stage (Islam et al., 2000) and is associated with an unfavorable prognosis (Tajiri et al., 2001; Miller et al., 2006) . Survivin overexpression was reported to increase proliferation and to protect tumor cells against apoptosis by various stimuli (Ambrosini et al., 1997; Islam et al., 2000) . There is also evidence that Survivin is regulated by targets of the PI3K-PKB pathway in neuronal cells: vascular endothelial growth factor-induced expression of Survivin in NB is blocked by the PI3K inhibitor Ly294002, suggesting that Survivin is regulated downstream of PI3K (Beierle et al., 2005) . A role of the PI3K-PKB pathway in Survivin regulation is further supported by the observation that dominant-negative PI3K decreases Survivin and c-IAP1 mRNA and protein expression in various NB cell lines (Kim et al., 2004) . Our data imply that the transcription factor FKHRL1 might be a missing link between PI3K-PKB and Survivin in NB cells. Importantly, Survivin was not only repressed by FKHRL1 but also protected against FKHRL1-induced apoptosis ( Figure 4B) and FKHRL1-induced drug sensitization (Figure 7, D and E) . Survivin knockdown by retroviral shRNA technology, in contrast, markedly sensitized SH-EP cells to FKHRL1-induced death (Figure 5, B and C) . This supports the notion that Survivin steady-state levels critically modulate FKHRL1-induced apoptosis in NB cells. Whereas its function during mitosis and cytokinesis has been investigated in detail, the role of Survivin in protecting cells from apoptosis is less well understood. Because Survivin contains only a single BIR domain and lacks a RING structure, its activity as a caspaseinhibiting IAP is under debate. Interestingly, we observed that part of Survivin purified with the mitochondrial fraction in SH-EP/FKHRL1 cells. It was shown before that a pool of Survivin localizes to the intramitochondrial membrane space in mammalian cells. Mitochondrial Survivin binds BIRC4/XIAP and thereby prevents XIAP from polyubiquitination and proteasomal degradation (Dohi et al., 2004) . In response to mitochondrial permeabilization, the Survivin/XIAP complex is released into the cytosol where it inhibits caspase-9 activation (Dohi et al., 2007) . CeballosCancino et al. (2007) recently reported that mitochondrial Survivin prevents etoposide-induced cell death via binding to Smac/Diablo, thereby delaying its release from the mitochondrial intermembrane space into the cytosol. These data are consistent with our observation that repression of endogenous Survivin by FKHRL1 sensitized to the DNAdamaging compounds etoposide and doxorubicin and that transgenic Survivin diminished FKHRL1-induced drug sensitization (Figure 7, D and E) . Because FKHRL1-induced cell death in NB cells is controlled at the level of mitochondria (Obexer et al., 2007) , the ability of mitochondrial Survivin to bind Smac/Diablo and/or XIAP at the mitochondria might explain, at least in part, why stable Survivin knockdown lowers the threshold for apoptosis induction by FKHRL1 ( Figure 5 , B and C), whereas Survivin overexpression had the opposite effect ( Figure 4B ). The loss of endogenous, mitochondrial Survivin correlated with the release of cytochrome c to the cytosol in control cells. Interestingly, in Survivin-transgenic cells, only cytosolic Survivin was down-regulated by FKHRL1, whereas mitochondrial Survivin steady-state levels remained unaltered ( Figure 6B , bottom). This differential regulation of mitochondrial and cytoplasmic Survivin might be due to a lower turn over rate of mitochondrial Survivin (Dohi et al., 2007) . Thereby, as long as mitochondria are intact (as suggested by mitochondrial retention of cytochrome c) mitochondrial Survivin is protected from proteasomal degradation. The repression of endogenous Survivin by FKHRL1 may accelerate the release of Smac/Diablo during chemotherapy treatment (CeballosCancino et al., 2007) , which is otherwise blocked by mitochondrial Survivin. This effect might in particular be important in NB cells, where gain of 17q and elevated expression of Survivin in advanced stage tumors correlates with therapy resistance and adverse outcome (Islam et al., 2000) . However, Survivin seems to exert additional effects upstream of mitochondrial outer membrane permeabilization, because ectopic Survivin preserved mitochondrial activity ( Figure 6A ) and its knockdown accelerated mitochondrial breakdown during FKHRL1-induced cell death ( Figure 5C ). Furthermore, Survivin expression affected mitochondrial accumulation of proapoptotic Bim and BAX. The molecular basis for this observation is unclear and currently under investigation.
Because both high activity of PKB and deregulated expression of Survivin are prognostic for an adverse outcome in NB, strategies targeting FKHRL1 will have the advantage to activate death control downstream of PKB and to repress Survivin, which protects against DNA-damaging agents such as etoposide and doxorubicin. A decrease in Survivin will considerably lower drug concentrations necessary during chemotherapy and thereby also allow the reduction of therapy-induced side effects and long-term effects.
